These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30146055)

  • 1. The Power of Labeling in Nocebo Effects.
    Faasse K; Martin LR
    Int Rev Neurobiol; 2018; 139():379-406. PubMed ID: 30146055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of brand or generic labeling on medication effectiveness and side effects.
    Faasse K; Martin LR; Grey A; Gamble G; Petrie KJ
    Health Psychol; 2016 Feb; 35(2):187-90. PubMed ID: 26462056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
    PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.
    MacKrill K; Petrie KJ
    BMJ Open; 2018 Oct; 8(10):e023667. PubMed ID: 30341138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing understanding, perceptions, pain relief of and preference for generic medicines with patient education: An experimental intervention study.
    Kleinstäuber M; Colgan S; Petrie KJ
    Res Social Adm Pharm; 2021 Jul; 17(7):1288-1299. PubMed ID: 33012643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the longevity of attribute framing in attenuating the nocebo effect to brand and generic medication.
    Barnes K; Sydney K; Petkovich K; Hasan Y; Koul S; Humphreys K; Geers AL; Faasse K
    Appl Psychol Health Well Being; 2024 Jul; ():. PubMed ID: 38967323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brand loyalty, patients and limited generic medicines uptake.
    Costa-Font J; Rudisill C; Tan S
    Health Policy; 2014 Jun; 116(2-3):224-33. PubMed ID: 24573104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rebranding generic medicines on drug efficacy and side effects.
    MacKrill K; Kleinstäuber M; Petrie KJ
    Psychol Health; 2019 Dec; 34(12):1470-1485. PubMed ID: 31112047
    [No Abstract]   [Full Text] [Related]  

  • 10. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study.
    Corrao G; Soranna D; Merlino L; Mancia G
    Eur J Clin Invest; 2014 Oct; 44(10):933-9. PubMed ID: 25132063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generics versus brand-named drugs for glaucoma: the debate continues.
    Bhartiya S; Dhingra D
    Rom J Ophthalmol; 2020; 64(3):239-244. PubMed ID: 33367157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the opinions and experiences of patients with generic substitution: a representative study of Polish society.
    Drozdowska A; Hermanowski T
    Int J Clin Pharm; 2015 Feb; 37(1):68-75. PubMed ID: 25428446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic medications for you, but brand-name medications for me.
    Keenum AJ; Devoe JE; Chisolm DJ; Wallace LS
    Res Social Adm Pharm; 2012; 8(6):574-8. PubMed ID: 22357268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding authorized generics-A review of the published clinical data.
    Alderfer J; Hansen RA; Mattingly TJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1489-1497. PubMed ID: 33829528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "No generics, Doctor!" The perspective of general practitioners in two French regions.
    Riner B; Bussy A; Hélène-Pelage J; Moueza N; Lamy S; Carrère P
    BMC Health Serv Res; 2017 Nov; 17(1):707. PubMed ID: 29121918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing perceptions and efficacy of generic medicines: An intervention study.
    Colgan SL; Faasse K; Pereira JA; Grey A; Petrie KJ
    Health Psychol; 2016 Nov; 35(11):1246-1253. PubMed ID: 27505191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.